Praxis Precision Medicines, Inc. (PRAX) Stock Score, Valuation & Financial Research

Praxis Precision Medicines, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PRAX

Praxis Precision Medicines, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 239.02. These figures are a research snapshot, not a buy or sell recommendation.

What Praxis Precision Medicines, Inc. does

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Praxis Precision Medicines is a clinical-stage biopharmaceutical company that generates no commercial revenue. It focuses on the research and development of novel therapies for central nervous system disorders, relying on capital raises and potential future licensing or collaboration payments to fund its operations.

Products and services

  • The company develops a pipeline of small molecule and antisense oligonucleotide (ASO) product candidates targeting neurological disorders, including epilepsy and movement disorders.

Brands and product families

  • Cerebrum — Proprietary small molecule platform. Source
  • Solidus — Proprietary antisense oligonucleotide (ASO) platform. Source

Customer types

Healthcare providers and patients with CNS disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug candidates for clinical use; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Biopharmaceutical and biotechnology companies — The company competes with various entities developing therapies for epilepsy and movement disorders, including large pharmaceutical companies and smaller biotech firms. Source

Business strengths to evaluate

  • Proprietary small molecule (Cerebrum) and ASO (Solidus) platforms Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PRAX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 239.02
Market capitalization:
6.67B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -339.13M
Free cash flow:
USD -249.12M
Cash:
USD 474.76M
Total debt:
USD 1.09M
EPS:
USD -12.95

What stands out

  • Free cash flow is USD -249.12M, negative for the stored period.
  • The balance sheet shows USD 474.76M of cash versus USD 1.09M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 473.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PRAX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PRAX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PRAX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PRAX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PRAX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PRAX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.